Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: former_pgs who wrote (3649)	12/15/2005 5:41:36 PM
From: scaram(o)uche	Respond to of 12215

thanks! (eom)

To: former_pgs who wrote (3649)	12/15/2005 7:45:50 PM
From: John Metcalf	Read Replies (1) \| Respond to of 12215

speedel.com Thanks, pgs, for mention of Speedel. I haven't read all their website yet, put the pdf file above provides an overview in bullet points. SPPN.SW started trading on 9/8/05. At today's quote and currency rates (1 Swiss Franc = $.7745 USD), shares are going for $104, or $718mm market cap. They estimate burn at $47mm (USD) and have $89mm liquid (Sept 05). Only 8,500 shares per day are traded, so this may be hard to buy in the real world. SPP 301 is in Phase III; an Endothelin A receptor antagonist, partnered with Roche, and being tested in diabetic nephropathy. There were two renin inhibitor programs listed. SPP 100 is the one with Novartis in hypertension. Some Phase III data must have been released because the company commented that efficacy was good and there was "placebo-like safety". They intend to file NDA next quarter. SPP 635 is an un-partnered renin inhib in Ph I. There's also a phase II program with Abbott -- SPP 200, a direct thrombin inhibitor. They also mentioned an SPP 600 series, which is unpartnered (but also undescribed). I need to look a lot further, but particularly want to know terms of the partnerships. Without significant milestones, they'll have to raise new funds in 18 months. Thanks again for the idea.